文献速递糖尿病

达格列净联合沙格列汀与甘精胰岛素治疗后的持续葡萄糖监测图谱与健康结局对比

Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine.
PubMed 文献 · J Clin Endocrinol Metab · 2024-01-01

这项为期24周的多中心随机开放标签3b期研究的亚组分析,纳入283例二甲双胍±磺脲类控制不佳的2型糖尿病成人,比较达格列净联合沙格列汀与甘精胰岛素。两组HbA1c降幅相似,但达格列净联合沙格列汀组目标范围内时间更高、夜间低血糖时间更短、血糖波动更小,患者报告结局更好。

要点

  • 两组HbA1c降幅相似,组间均值差为-0.12%(95%CI -0.37至0.12%),P=0.33。
  • 达格列净联合沙格列汀组目标范围内时间34.3±1.9% vs 甘精胰岛素组28.5±1.9%,P=0.033。
  • 达格列净联合沙格列汀组夜间低血糖时间0.6±0.5% vs 甘精胰岛素组2.7±0.5%,P=0.007。

核心结论

  • 达格列净联合沙格列汀与甘精胰岛素在24周时降低HbA1c同样有效,但达格列净联合沙格列汀组目标范围内时间更高、血糖波动和变异性降幅更大、低血糖时间更少,患者报告的健康结局改善。

研究设计与样本

  • 随机、开放标签、2臂、平行组、3b期研究的24周亚组分析。
  • 多中心研究,涉及11个国家的112个中心。
  • 283例二甲双胍±磺脲类控制不佳的2型糖尿病成人。
  • 干预为达格列净联合沙格列汀 vs 甘精胰岛素。
  • 主要结局指标为持续葡萄糖监测图谱、HbA1c和患者报告结局的变化。

主要发现

  • 达格列净联合沙格列汀组HbA1c自基线降幅与甘精胰岛素组相似,降幅间均值差为-0.12%(95%CI -0.37至0.12%),P=0.33。
  • 达格列净联合沙格列汀组目标范围内时间(>3.9且≤10 mmol/L)为34.3±1.9% vs 甘精胰岛素组28.5±1.9%,P=0.033。
  • 达格列净联合沙格列汀组夜间低血糖时间(曲线下面积≤3.9 mmol/L)为0.6±0.5% vs 甘精胰岛素组2.7±0.5%,P=0.007。
  • 达格列净联合沙格列汀组血糖波动平均幅度为-0.7±0.1 mmol/L vs 甘精胰岛素组-0.3±0.1 mmol/L,P=0.017。
  • 持续葡萄糖监测指标改善与更高的满意度、更好的体重形象、更少的体重干扰以及改善的心理和情绪健康相关。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Glycemic variability and hypoglycemia during diabetes treatment may impact therapeutic effectiveness and safety, even when glycated hemoglobin (HbA1c) reduction is comparable between therapies. OBJECTIVE: We employed masked continuous glucose monitoring (CGM) during a randomized trial of dapagliflozin plus saxagliptin (DAPA + SAXA) vs insulin glargine (INS) to compare glucose variability and patient-reported outcomes (PROs). DESIGN: 24-week substudy of a randomized, open-label, 2-arm, parallel-group, phase 3b study. SETTING: Multicenter study (112 centers in 11 countries). PATIENTS: 283 adults with type 2 diabetes (T2D) inadequately controlled with metformin ± sulfonylurea. INTERVENTIONS: DAPA + SAXA vs INS. MAIN OUTCOME MEASURES: Changes in CGM profiles, HbA1c, and PROs. RESULTS: Changes from baseline in HbA1c with DAPA + SAXA were similar to those observed with INS, with mean difference [95% confidence interval] between decreases of -0.12% [-0.37 to 0.12%], P = .33. CGM analytics were more favorable for DAPA + SAXA, including greater percent time in range (> 3.9 and ≤ 10 mmol/L; 34.3 ± 1.9 vs 28.5 ± 1.9%, P = .033), lower percent time with nocturnal hypoglycemia (area under the curve ≤ 3.9 mmol/L; 0.6 ± 0.5 vs 2.7 ± 0.5%, P = .007), and smaller mean amplitude of glycemic excursions (-0.7 ± 0.1 vs -0.3 ± 0.1 mmol/L, P = .017). Improvements in CGM were associated with greater satisfaction, better body weight image, less weight interference, and improved mental and emotional well-being. CONCLUSION: DAPA + SAXA and INS were equally effective in reducing HbA1c at 24 weeks, but people with T2D treated with DAPA + SAXA achieved greater time in range, greater reductions in glycemic excursions and variability, less time with hypoglycemia, and improved patient-reported health outcomes.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Simonson DC, Testa MA, Ekholm E, et al. Continuous Glucose Monitoring Profiles and Health Outcomes After Dapagliflozin Plus Saxagliptin vs Insulin Glargine. J Clin Endocrinol Metab. 2024. PMID: 38412282. doi:10.1210/clinem/dgae105

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。